{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:46:38Z","timestamp":1791413198227,"version":"4.3.3"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K24-AI093969"],"award-info":[{"award-number":["K24-AI093969"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5UM1AI104681"],"award-info":[{"award-number":["5UM1AI104681"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013993","name":"Theravance Biopharma US, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013993","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,15]]},"DOI":"10.1093\/cid\/ciy774","type":"journal-article","created":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T23:13:58Z","timestamp":1536189238000},"page":"865-872","source":"Crossref","is-referenced-by-count":38,"title":["Considerations for Clinical Trials of\n                    <i>Staphylococcus aureus<\/i>\n                    Bloodstream Infection in Adults"],"prefix":"10.1093","volume":"68","author":[{"given":"Thomas L","family":"Holland","sequence":"first","affiliation":[{"name":"Department of Medicine, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry F","family":"Chambers","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen W","family":"Boucher","sequence":"additional","affiliation":[{"name":"Department of Medicine, Tufts Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Ralph","family":"Corey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Coleman","sequence":"additional","affiliation":[{"name":"Theravance Biopharma US, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bibiana","family":"Castaneda-Ruiz","sequence":"additional","affiliation":[{"name":"Theravance Biopharma US, Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Vance G","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"key":"key\n\t\t\t\t2019021500003274900_CIT0001","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0002","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","article-title":"Clinical management of Staphylococcus aureus bacteremia: a review","volume":"312","author":"Holland","year":"2014","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0003","volume-title":"Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment","author":"US Food and Drug Administration","year":"2013"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0004","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1086\/533441","article-title":"Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia","volume":"46","author":"Pertel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0005","doi-asserted-by":"crossref","first-page":"h2219","DOI":"10.1136\/bmj.h2219","article-title":"Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial","volume":"350","author":"Paul","year":"2015","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0006","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0007","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1086\/653519","article-title":"Serious infections caused by methicillin-resistant Staphylococcus aureus","volume":"51","author":"Boucher","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0008","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1086\/647937","article-title":"Challenges in anti-infective development in the era of bad bugs, no drugs: a regulatory perspective using the example of bloodstream infection as an indication","volume":"50","author":"Boucher","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0009","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(17)32456-X","article-title":"Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Thwaites","year":"2018","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0010","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/jama.2018.13155","article-title":"Effect of algorithm-based therapy vs usual care on clinical success and serious adverse events in patients with Staphylococcal bacteremia","volume":"320","author":"Holland","year":"2018","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0011","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0012","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2334-14-289","article-title":"A randomized phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study","volume":"14","author":"Stryjewski","year":"2014","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0013","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1128\/AAC.00096-06","article-title":"Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia","volume":"50","author":"Weems","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0014","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1128\/AAC.00570-07","article-title":"Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia","volume":"51","author":"Rupp","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/jac\/dku322","article-title":"Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia","volume":"70","author":"Barber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0016","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1128\/AAC.04141-14","article-title":"Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections","volume":"59","author":"Claeys","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0017","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0018","first-page":"MR000043","article-title":"Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimates","volume":"3","author":"Ndounga Diakou","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0019","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent Staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0020","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1001\/archinte.163.17.2066","article-title":"Clinical identifiers of complicated Staphylococcus aureus bacteremia","volume":"163","author":"Fowler","year":"2003","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0021","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-140-1-200401060-00008","article-title":"International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections","volume":"140","author":"Paterson","year":"2004","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0022","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0023","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0024","volume-title":"Guidance for industry. Community-acquired bacterial pneumonia: developing drugs for treatment","author":"US Food and Drug Administration","year":"2014"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0025","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/01.md.0000091185.93122.40","article-title":"A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0026","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1128\/AAC.01021-12","article-title":"Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study","volume":"57","author":"Chong","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0027","doi-asserted-by":"crossref","first-page":"e01043","DOI":"10.1128\/AAC.01043-17","article-title":"Antimicrobial susceptibility trends among Staphylococcus aureus isolates from U.S. hospitals: results from 7 years of the ceftaroline (AWARE) surveillance program, 2010 to 2016","volume":"61","author":"Sader","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0028","doi-asserted-by":"crossref","first-page":"e0170236","DOI":"10.1371\/journal.pone.0170236","article-title":"Characteristics of Staphylococcus aureus bacteraemia and predictors of early and late mortality","volume":"12","author":"Bassetti","year":"2017","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0029","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/512627","article-title":"Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus","volume":"28","author":"Shurland","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0030","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/hrt.2003.025585","article-title":"Repeated echocardiographic examinations of patients with suspected infective endocarditis","volume":"90","author":"Vieira","year":"2004","journal-title":"Heart"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0031","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.2967\/jnumed.117.191981","article-title":"18F-FDG PET\/CT optimizes treatment in Staphylococcus aureus bacteremia and is associated with reduced mortality","volume":"58","author":"Berrevoets","year":"2017","journal-title":"J Nucl Med"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0032","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/hc3401.095097","article-title":"Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators","volume":"104","author":"Chamis","year":"2001","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0033","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1086\/514686","article-title":"Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients","volume":"27","author":"Fowler","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0034","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1056\/NEJMoa1112843","article-title":"Early surgery versus conventional treatment for infective endocarditis","volume":"366","author":"Kang","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0035","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/cid\/ciu871","article-title":"Impact of early valve surgery on outcome of Staphylococcus aureus prosthetic valve infective endocarditis: analysis in the International Collaboration of Endocarditis-Prospective Cohort Study","volume":"60","author":"Chirouze","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0036","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cmi.2016.10.023","article-title":"Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition","volume":"23","author":"Harris","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0037","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/01.md.0000091184.93122.09","article-title":"Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study","volume":"82","author":"Chang","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0038","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0039","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/19466315.2016.1207561","article-title":"Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation","volume":"8","author":"Evans","year":"2016","journal-title":"Stat Biopharm Res"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0040","article-title":"BAC DOOR: a clinician ranking exercise for better Staphylococcus aureus bacteremia trial design","volume":"3","author":"Doernberg","journal-title":"Open Forum Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0041","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals","volume":"61","author":"McDanel","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0042","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2334-11-279","article-title":"Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia","volume":"11","author":"Schweizer","year":"2011","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0043","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/cid\/cit582","article-title":"Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia","volume":"57","author":"Falcone","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0044","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","article-title":"Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program","volume":"49","author":"Figueroa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0045","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/597031","article-title":"Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic","volume":"48","author":"Cosgrove","year":"2009","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0046","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/cid\/ciu580","article-title":"Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial","volume":"59","author":"del R\u00edo","year":"2014","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0047","doi-asserted-by":"crossref","first-page":"ofu046","DOI":"10.1093\/ofid\/ofu046","article-title":"Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis","volume":"1","author":"Fabre","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"key\n\t\t\t\t2019021500003274900_CIT0048","unstructured":"Boucher\n              H.\n            \n          \n          S. aureus bacteremia and endocarditis study efficacy results. In: US Food and Drug Administration, Center for Drug Evaluation and Research: Anti-Infective Drugs Advisory Committee, 6 March 2006. Available at: https:\/\/wayback.archive-it.org\/7993\/20170404052335\/https:\/www.fda.gov\/ohrms\/dockets\/ac\/06\/slides\/2006-4209S1-index.htm. Accessed 14 May 2018."}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/5\/865\/27783813\/ciy774.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:01:54Z","timestamp":1550188914000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/5\/865\/5094535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,9,10]]},"published-print":{"date-parts":[[2019,2,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy774","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733991402.793587625","asserted-by":"object"}]},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3,1]]},"published":{"date-parts":[[2018,9,10]]}}}